NO983876D0 - Syntetiske HIV-gener - Google Patents

Syntetiske HIV-gener

Info

Publication number
NO983876D0
NO983876D0 NO983876A NO983876A NO983876D0 NO 983876 D0 NO983876 D0 NO 983876D0 NO 983876 A NO983876 A NO 983876A NO 983876 A NO983876 A NO 983876A NO 983876 D0 NO983876 D0 NO 983876D0
Authority
NO
Norway
Prior art keywords
synthetic hiv
hiv genes
genes
synthetic
hiv
Prior art date
Application number
NO983876A
Other languages
English (en)
Other versions
NO983876L (no
Inventor
John W Shiver
Mary-Ellen Davies
Daniel C Freed
Margaret A Liu
Helen C Perry
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9607293.9A external-priority patent/GB9607293D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO983876D0 publication Critical patent/NO983876D0/no
Publication of NO983876L publication Critical patent/NO983876L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO983876A 1996-02-22 1998-08-21 Syntetiske HIV-gener NO983876L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1208296P 1996-02-22 1996-02-22
GBGB9607293.9A GB9607293D0 (en) 1996-04-09 1996-04-09 Synthetic hiv env genes
PCT/US1997/002294 WO1997031115A2 (en) 1996-02-22 1997-02-18 Synthetic hiv genes

Publications (2)

Publication Number Publication Date
NO983876D0 true NO983876D0 (no) 1998-08-21
NO983876L NO983876L (no) 1998-10-21

Family

ID=26309076

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983876A NO983876L (no) 1996-02-22 1998-08-21 Syntetiske HIV-gener

Country Status (27)

Country Link
EP (1) EP0904380B1 (no)
JP (1) JP2000505299A (no)
KR (1) KR19990087126A (no)
CN (1) CN1216064A (no)
AR (1) AR005930A1 (no)
AT (1) ATE309366T1 (no)
AU (1) AU729231B2 (no)
BG (1) BG102784A (no)
BR (1) BR9707672A (no)
CO (1) CO4600706A1 (no)
CZ (1) CZ266798A3 (no)
DE (1) DE69734585T2 (no)
EE (1) EE9800257A (no)
ES (1) ES2251734T3 (no)
HR (1) HRP970092A2 (no)
HU (1) HUP9901112A3 (no)
ID (1) ID16021A (no)
IL (1) IL125547A0 (no)
IS (1) IS4814A (no)
NO (1) NO983876L (no)
NZ (1) NZ331161A (no)
PE (1) PE43298A1 (no)
PL (1) PL328730A1 (no)
SK (1) SK112998A3 (no)
TR (1) TR199801615T2 (no)
WO (1) WO1997031115A2 (no)
YU (1) YU35498A (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534312B1 (en) 1996-02-22 2003-03-18 Merck & Co., Inc. Vaccines comprising synthetic genes
WO1997048370A2 (en) * 1996-06-21 1997-12-24 Merck & Co., Inc. Vaccines comprising synthetic genes
US6696291B2 (en) 1997-02-07 2004-02-24 Merck & Co., Inc. Synthetic HIV gag genes
CA2280195A1 (en) * 1997-02-07 1998-08-13 Merck & Co., Inc. Synthetic hiv gag genes
JP2001519663A (ja) 1997-04-04 2001-10-23 ピー． ウィークス、ドナルド 遺伝子導入ジカンバ−分解生物体を製造及び使用するための方法及び材料
US7105724B2 (en) 1997-04-04 2006-09-12 Board Of Regents Of University Of Nebraska Methods and materials for making and using transgenic dicamba-degrading organisms
JP2001520048A (ja) 1997-10-20 2001-10-30 ジェンザイム トランスジェニックス コーポレイション 新規な改変されたＭＳＰ−１核酸配列並びに細胞システムにおいてｍＲＮＡレベル及び蛋白質発現を増大させる方法
AU2003200914B2 (en) * 1997-10-20 2007-02-01 Gtc Biotherapeutics, Inc. Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US6924365B1 (en) 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
WO2000039304A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
EP1535995A1 (en) * 1998-12-31 2005-06-01 Chiron Corporation Polynucleotides encoding the antigenic HIV type C env polypeptide and uses thereof
EP1980617A1 (en) * 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Improved expression of HIV polypeptides and production of virus-like particles
EP1433851A3 (en) * 1998-12-31 2004-10-13 Chiron Corporation Improved expression of HIV polypeptides and production of virus-like particles
US6395714B1 (en) * 1999-02-24 2002-05-28 Aventis Pasteur Limited Expressing gp140 fragment of primary HIV-1 isolate
AU778809B2 (en) 1999-03-29 2004-12-23 Statens Serum Institut Method for producing a nucleotide sequence construct with optimised codons for an HIV genetic vaccine based on primary, early HIV isolate and synthetic envelope BX08 constructs
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
WO2001002607A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
AU2400500A (en) 1999-11-01 2001-05-14 Chiron Corporation Expression vectors, transfection systems, and method of use thereof
CA2395429A1 (en) * 1999-12-22 2001-06-28 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol
GB0014288D0 (en) 2000-06-10 2000-08-02 Smithkline Beecham Biolog Vaccine
GB0017990D0 (en) 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
EP1322338A4 (en) * 2000-10-04 2005-04-13 Univ Pennsylvania COMPOSITIONS AND METHODS OF USING A CAPSID PROTEIN FROM VARIOUS FLAVIVIRUS AND PESTIVIRUS
KR20020059856A (ko) * 2001-01-08 2002-07-16 김철중 에이치아이브이 유사입자의 제조
CA2452015C (en) 2001-07-05 2012-07-03 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
MXPA04002631A (es) * 2001-09-20 2004-07-08 Glaxo Group Ltd Vacunas de adn optimizadas por codon gag-vih.
AU2004308964B2 (en) 2003-12-23 2010-09-16 Arbor Vita Corporation Antibodies for oncogenic strains of HPV and methods of their use
US7855326B2 (en) 2006-06-06 2010-12-21 Monsanto Technology Llc Methods for weed control using plants having dicamba-degrading enzymatic activity
US8754011B2 (en) 2006-10-16 2014-06-17 Monsanto Technology Llc Methods and compositions for improving plant health
US7838729B2 (en) 2007-02-26 2010-11-23 Monsanto Technology Llc Chloroplast transit peptides for efficient targeting of DMO and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016737A1 (en) * 1993-01-26 1994-08-04 Weiner David B Compositions and methods for delivery of genetic material
CA2181832C (en) * 1994-01-27 2012-11-27 Harriet L. Robinson Immunization by inoculation of dna transcription unit
US6630455B1 (en) * 1995-01-13 2003-10-07 Vanderbilt University Methods for inducing mucosal immune responses
JPH08198774A (ja) * 1995-01-20 1996-08-06 Terumo Corp Ｄｎａワクチン

Also Published As

Publication number Publication date
AU729231B2 (en) 2001-01-25
ES2251734T3 (es) 2006-05-01
SK112998A3 (en) 2000-04-10
EP0904380A2 (en) 1999-03-31
WO1997031115A3 (en) 1997-10-09
CN1216064A (zh) 1999-05-05
JP2000505299A (ja) 2000-05-09
CO4600706A1 (es) 1998-05-08
EE9800257A (et) 1999-02-15
WO1997031115A2 (en) 1997-08-28
PE43298A1 (es) 1998-08-29
ID16021A (id) 1997-08-28
CZ266798A3 (cs) 1999-03-17
KR19990087126A (ko) 1999-12-15
DE69734585D1 (de) 2005-12-15
IL125547A0 (en) 1999-03-12
NO983876L (no) 1998-10-21
AR005930A1 (es) 1999-07-21
HRP970092A2 (en) 1998-04-30
PL328730A1 (en) 1999-02-15
HUP9901112A2 (hu) 1999-07-28
NZ331161A (en) 2000-03-27
DE69734585T2 (de) 2006-08-10
HUP9901112A3 (en) 2001-06-28
ATE309366T1 (de) 2005-11-15
EP0904380B1 (en) 2005-11-09
YU35498A (sh) 1999-07-28
AU2124697A (en) 1997-09-10
IS4814A (is) 1998-07-30
BR9707672A (pt) 1999-04-13
BG102784A (en) 1999-05-31
TR199801615T2 (xx) 1998-11-23

Similar Documents

Publication Publication Date Title
EE9800257A (et) Sünteetilised HIV geenid
IT1295009B1 (it) Idrossifeniltriazine
NO996435D0 (no) Polymerisasjonsprosess
NO970520D0 (no) Ett-trinns-vindusutboringssystem
DK0942905T3 (da) 3-Amino-1-cyanophenyl-uraciler
DE59709322D1 (de) Ferrocenderivate
DE69718354D1 (de) Papierklammer
NO20003168D0 (no) Polymerisasjonsmetode
DE59810608D1 (de) Stapelvorrichtung
ID16013A (id) PEROLEHAN ε-KAPROLAKTAM
ID16421A (id) Gen-gen sintetik
NO993432D0 (no) Polymerisasjonsprosess
FI964006A0 (fi) Skoerdetroeska
EP0949331A4 (en) Established microglial cells
NO984671D0 (no) Organofosforsammensetninger
DE69835157D1 (de) Reihenelektroden-anodisierung
KR970002029U (ko) 납골묘
FR2770103B1 (fr) Bigoudi perfectionne
SE9601422D0 (sv) Synthetic genes
SE9603469D0 (sv) Synthetic genes
FI100512B (fi) Lehtiötaulu
NO996436D0 (no) Polymerisasjonskatalysator
FI2369U1 (fi) Sarjalomake
KR970051149U (ko) 여러가지 돌아이바이
BR9600867A (pt) Conjunto empacotadora-enfardadora

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application